Advertisement

Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis

      Abstract

      Objective

      Phospholipid transfer protein (PLTP) facilitates cholesterol efflux from cells, intravascular HDL remodelling and transfer of vitamin E and endotoxin. In humans, the relationship of PLTP to atherosclerosis is unknown. However, strong coronary risk factors like obesity, diabetes, cigarette smoking and inflammation increase circulating levels of active PLTP. The aim of the present, cross-sectional study was to analyze the relationship of PLTP to peripheral arterial disease, a marker of generalized atherosclerosis, independently of potentially confounding factors like obesity, diabetes and smoking.

      Methods

      We performed a case control study in 153 patients with symptomatic peripheral arterial disease (PAD) and 208 controls free of vascular disease. Smokers and patients with diabetes mellitus were excluded. A lipoprotein-independent assay was used for measurement of circulating bioactive PLTP and an ELISA utilizing a monoclonal antibody was used to analyze PLTP mass.

      Results

      PLTP activity was significantly decreased in patients with PAD 5.5 (4.6–6.4)(median (25th–75th percentile)) versus 5.9 (5.1–6.9) μmol/mL/h in controls (p = 0.001). In contrast, PLTP mass was similar in patients with PAD 8.5 μg/mL (7.3–9.5) and in controls 8.3 μg/mL (6.9–9.7) (p = 0.665). Multivariate logistic regression analysis revealed that PLTP activity is independently associated with the presence of PAD. PLTP activity was similar in patients with and without lipid-lowering drugs (p = 0.396).

      Conclusion

      Our results show that in non-diabetic, non-smoking subjects low rather than high PLTP activity is a marker for the presence of peripheral arterial disease and that distribution of PLTP between high-activity and low-activity forms may be compromised in atherosclerosis.

      Abbreviations:

      ABI (ankle brachial index), CAD (coronary arterial disease), CVD (cerebral vascular disease), HbA1C (glycohemoglobine A1C), HDL (high-density lipoprotein), hs-CRP (high-sensitivity C-reactive protein), LDL (low-density lipoprotein), OR (odds ratio), PAD (peripheral arterial disease), PC (phosphatidyl choline), PLTP (phospholipid transfer protein)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Huuskonen J.
        • Olkkonen V.M.
        • Jauhiainen M.
        • Ehnholm C.
        The impact of phospholipid transfer protein (PLTP) on HDL metabolism.
        Atherosclerosis. 2001; 155: 269-281
        • Wolfbauer G.
        • Albers J.J.
        • Oram J.F.
        Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins.
        Biochim Biophys Acta. 1999; 1439: 65-76
        • Oram J.F.
        • Wolfbauer G.
        • Vaughan A.M.
        • Tang C.
        • Albers J.J.
        Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells.
        J Biol Chem. 2003; 278: 52379-52385
        • Tall A.R.
        • Abreu E.
        • Shuman J.
        Separation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein.
        J Biol Chem. 1983; 258: 2174-2180
        • Rye K.A.
        • Barter P.J.
        Changes in the size and density of human high-density lipoproteins promoted by a plasma-conversion factor.
        Biochim Biophys Acta. 1986; 875: 429-438
        • Jauhiainen M.
        • Metso J.
        • Pahlman R.
        • Blomqvist S.
        • van Tol A.
        • Ehnholm C.
        Human plasma phospholipid transfer protein causes high density lipoprotein conversion.
        J Biol Chem. 1993; 268: 4032-4036
        • Tu A.Y.
        • Nishida H.I.
        • Nishida T.
        High density lipoprotein conversion mediated by human plasma phospholipid transfer protein.
        J Biol Chem. 1993; 268: 23098-23105
        • von Eckardstein A.
        • Jauhiainen M.
        • Huang Y.
        • et al.
        Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre beta 1-HDL.
        Biochim Biophys Acta. 1996; 1301: 255-262
        • Foger B.
        • Santamarina-Fojo S.
        • Shamburek R.D.
        • et al.
        Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL.
        J Biol Chem. 1997; 272: 27393-27400
        • Jiang X.C.
        • Qin S.
        • Qiao C.
        • et al.
        Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency.
        Nat Med. 2001; 7: 847-852
        • Desrumaux C.
        • Deckert V.
        • Athias A.
        • et al.
        Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells.
        FASEB J. 1999; 13: 883-892
        • Levels J.H.
        • Marquart J.A.
        • Abraham P.R.
        • et al.
        Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein.
        Infect Immun. 2005; 73: 2321-2326
        • van Haperen R.
        • van Tol A.
        • van Gent T.
        • et al.
        Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein.
        J Biol Chem. 2002; 277: 48938-48943
        • Yang X.P.
        • Yan D.
        • Qiao C.
        • et al.
        Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression.
        Arterioscler Thromb Vasc Biol. 2003; 23: 1601-1607
        • Jiang X.C.
        • Bruce C.
        • Mar J.
        • et al.
        Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels.
        J Clin Invest. 1999; 103: 907-914
        • Jiang X.C.
        • Tall A.R.
        • Qin S.
        • et al.
        Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E.
        J Biol Chem. 2002; 277: 31850-31856
        • Navab M.
        • Ananthramaiah G.M.
        • Reddy S.T.
        • et al.
        The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.
        J Lipid Res. 2004; 45: 993-1007
        • Janis M.T.
        • Siggins S.
        • Tahvanainen E.
        • et al.
        Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample.
        J Lipid Res. 2004; 45: 2303-2309
        • Valenta D.T.
        • Ogier N.
        • Bradshaw G.
        • et al.
        Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression.
        Arterioscler Thromb Vasc Biol. 2006; 26: 1572-1578
        • Vikstedt R.
        • Ye D.
        • Metso J.
        • et al.
        Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development.
        Arterioscler Thromb Vasc Biol. 2007; 27: 578-586
        • Liu R.
        • Hojjati M.R.
        • Devlin C.M.
        • Hansen I.H.
        • Jiang X.C.
        Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis.
        Arterioscler Thromb Vasc Biol. 2007; 27: 190-196
        • Tahvanainen E.
        • Jauhiainen M.
        • Funke H.
        • et al.
        Serum phospholipid transfer protein activity and genetic variation of the PLTP gene.
        Atherosclerosis. 1999; 146: 107-115
        • Dullaart R.P.
        • Sluiter W.J.
        • Dikkeschei L.D.
        • Hoogenberg K.
        • Van Tol A.
        Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism.
        Eur J Clin Invest. 1994; 24: 188-194
        • Riemens S.C.
        • van Tol A.
        • Sluiter W.J.
        • Dullaart R.P.
        Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients.
        Diabetologia. 1998; 41: 929-934
        • Kaser S.
        • Laimer M.
        • Sandhofer A.
        • et al.
        Effects of weight loss on PLTP activity and HDL particle size.
        Int J Obes Relat Metab Disord. 2004; 28: 1280-1282
        • Murdoch S.J.
        • Kahn S.E.
        • Albers J.J.
        • Brunzell J.D.
        • Purnell J.Q.
        PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity.
        J Lipid Res. 2003; 44: 1705-1712
        • Huuskonen J.
        • Ekstrom M.
        • Tahvanainen E.
        • et al.
        Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity.
        Atherosclerosis. 2000; 151: 451-461
        • Dullaart R.P.
        • Hoogenberg K.
        • Dikkeschei B.D.
        • van Tol A.
        Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men.
        Arterioscler Thromb. 1994; 14: 1581-1585
        • Cheung M.C.
        • Brown B.G.
        • Marino Larsen E.K.
        • Frutkin A.D.
        • O’Brien K.D.
        • Albers J.J.
        Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease.
        Biochim Biophys Acta. 2006; 1762: 131-137
        • Jonkers I.J.
        • Smelt A.H.
        • Hattori H.
        • et al.
        Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.
        J Lipid Res. 2003; 44: 1462-1469
        • Colhoun H.M.
        • Scheek L.M.
        • Rubens M.B.
        • et al.
        Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification.
        Diabetes. 2001; 50: 652-659
        • Schlitt A.
        • Bickel C.
        • Thumma P.
        • et al.
        High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease.
        Arterioscler Thromb Vasc Biol. 2003; 23: 1857-1862
        • Schlitt A.
        • Blankenberg S.
        • Rupprecht H.J.
        • et al.
        Prognostic value of classical and modern markers of lipoprotein-metabolism among elderly with CAD, only apoA-I is an independent predictor for event free survival.
        Eur Heart J. 2006; 27: 850
        • Yatsuya H.
        • Tamakoshi K.
        • Hattori H.
        • et al.
        Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases.
        Circ J. 2004; 68: 11-16
        • Ruhling K.
        • Lang A.
        • Richard F.
        • et al.
        Net mass transfer of plasma cholesteryl esters and lipid transfer proteins in normolipidemic patients with peripheral vascular disease.
        Metabolism. 1999; 48: 1361-1366
        • Mueller T.
        • Marschon R.
        • Dieplinger B.
        • et al.
        Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study.
        J Vasc Surg. 2005; 41: 808-815
        • Damen J.
        • Regts J.
        • Scherphof G.
        Transfer of [14C]phosphatidylcholine between liposomes and human plasma high density lipoprotein. Partial purification of a transfer-stimulating plasma factor using a rapid transfer assay.
        Biochim Biophys Acta. 1982; 712: 444-452
        • Ritsch A.
        • Patsch J.R.
        Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target.
        Curr Opin Lipidol. 2003; 14: 173-179
        • Foger B.
        • Chase M.
        • Amar M.J.
        • et al.
        Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.
        J Biol Chem. 1999; 274: 36912-36920
        • Oka T.
        • Yamashita S.
        • Kujiraoka T.
        • et al.
        Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia.
        J Lipid Res. 2002; 43: 1236-1243
        • Cheung M.C.
        • Knopp R.H.
        • Retzlaff B.
        • et al.
        Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity.
        Biochim Biophys Acta. 2002; 1587: 53-59
        • Geesje M.
        • Dallinga-Thie A.V.T.
        Apolipoprotein E is a determinant of PLTP activity in plasma from Type 2 diabetes mellitus patients: effects of atorvastatin treatment.
        Diabetes Suppl. 2005; 54: A1
        • Lagrost L.
        • Athias A.
        • Lemort N.
        • et al.
        Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin.
        Atherosclerosis. 1999; 143: 415-425
        • Cheung M.C.
        • Wolfbauer G.
        • Kennedy H.
        • Brown B.G.
        • Albers J.J.
        Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin.
        Biochim Biophys Acta. 2001; 1537: 117-124
        • Karkkainen M.
        • Oka T.
        • Olkkonen V.M.
        • et al.
        Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP).
        J Biol Chem. 2002; 277: 15413-15418
        • Oka T.
        • Kujiraoka T.
        • Ito M.
        • et al.
        Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive.
        J Lipid Res. 2000; 41: 1651-1657
        • Cheung M.C.
        • Albers J.J.
        Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins.
        J Lipid Res. 2006; 47: 1315-1321
        • Janis M.T.
        • Metso J.
        • Lankinen H.
        • et al.
        Apolipoprotein E activates the low-activity form of human phospholipid transfer protein.
        Biochem Biophys Res Commun. 2005; 331: 333-340
        • Tan K.C.
        • Shiu S.W.
        • Wong Y.
        • Wong W.K.
        • Tam S.
        Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in type 2 diabetes mellitus.
        Diabetes Metab Res Rev. 2006; 22: 307-312
        • Lee-Rueckert M.
        • Vikstedt R.
        • Metso J.
        • et al.
        Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells.
        J Lipid Res. 2006; 47: 1725-1732
        • Barlage S.
        • Frohlich D.
        • Bottcher A.
        • et al.
        ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response.
        J Lipid Res. 2001; 42: 281-290